These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10507996)

  • 1. Intention-to-treat analysis of anti-HIV therapies and incidence of drug resistance after a year of treatment.
    Aizawa S; Ida S; Sakai-Hachiya A; Tanaka M; Takahashi Y; Hirabayashi Y; Sugiura W; Kimura S; Oka S
    Jpn J Infect Dis; 1999 Jun; 52(3):129-31. PubMed ID: 10507996
    [No Abstract]   [Full Text] [Related]  

  • 2. [Light and shade on the treatment of HIV infection].
    Takata N
    Rinsho Ketsueki; 2001 Jun; 42(6):476-80. PubMed ID: 11505526
    [No Abstract]   [Full Text] [Related]  

  • 3. How testing for HIV resistance influences therapeutic decision making. Analysis of a sample of 600 clinicians.
    Mascolini M; Wensing AM; Boucher CA
    IAPAC Mon; 2001 Mar; 7(3):85-90. PubMed ID: 11697306
    [No Abstract]   [Full Text] [Related]  

  • 4. [Monitoring anti-retroviral treatment].
    Miró JM; Pumarola T; Soriano V; Bouza E
    Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():44-50. PubMed ID: 9053027
    [No Abstract]   [Full Text] [Related]  

  • 5. Understanding the principles of anti-HIV drug therapy.
    Horn T
    Surviv News (Atlanta Ga); 2001 Jul; ():13. PubMed ID: 11683014
    [No Abstract]   [Full Text] [Related]  

  • 6. Retrospective analysis of antiretroviral HIV treatment success based on medical history or guided by the reverse hybridisation LiPA HIV genotyping system.
    Alvarez M; García F; Martínez NM; Hernández Quero J; Louwagie J; De Brauwer A; Maroto MC
    J Med Virol; 2004 Jun; 73(2):151-7. PubMed ID: 15122786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapies. Confronting the limits of success.
    Cohen J
    Science; 2002 Jun; 296(5577):2320-4. PubMed ID: 12089422
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count.
    Jaafar A; Massip P; Sandres-Sauné K; Souyris C; Pasquier C; Aquilina C; Izopet J
    J Med Virol; 2004 Sep; 74(1):8-15. PubMed ID: 15258962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.
    Chkhartishvili N; Dvali N; Gochitashvili N; Sharvadze L; Tsertsvadze T
    Georgian Med News; 2008 Dec; (165):16-22. PubMed ID: 19124911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV/AIDS. Experts question danger of 'AIDS superbug'.
    Cohen J
    Science; 2005 Feb; 307(5713):1185. PubMed ID: 15731415
    [No Abstract]   [Full Text] [Related]  

  • 11. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SPV-30 shows encouraging results.
    AIDS Patient Care STDS; 1996 Jun; 10(3):186-7. PubMed ID: 11361631
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between drug resistance mutations, plasma viremia, and CD4+ T-cell counts in patients with chronic HIV infection.
    de Mendoza C; Martín-Carbonero L; Gallego O; Corral A; González-Lahoz J; Soriano V
    J Med Virol; 2005 May; 76(1):1-6. PubMed ID: 15778973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
    Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV drug resistance testing: data be damned.
    Res Initiat Treat Action; 2000 Dec; 6(4):25-7. PubMed ID: 11708172
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
    Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
    Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
    [No Abstract]   [Full Text] [Related]  

  • 19. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
    Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
    Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
    Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
    J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.